These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23339054)

  • 1. Caffeine consumption and risk of dyskinesia in CALM-PD.
    Wills AM; Eberly S; Tennis M; Lang AE; Messing S; Togasaki D; Tanner CM; Kamp C; Chen JF; Oakes D; McDermott MP; Schwarzschild MA;
    Mov Disord; 2013 Mar; 28(3):380-3. PubMed ID: 23339054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cup of coffee a day keeps dyskinesia away?
    Jenner P
    Mov Disord; 2013 Mar; 28(3):265-7. PubMed ID: 23447426
    [No Abstract]   [Full Text] [Related]  

  • 3. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pramipexole on the onset of levodopa-related dyskinesias.
    Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
    Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
    Brodsky MA; Park BS; Nutt JG
    Arch Neurol; 2010 Jan; 67(1):27-32. PubMed ID: 20065126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
    Xiao D; Cassin JJ; Healy B; Burdett TC; Chen JF; Fredholm BB; Schwarzschild MA
    Brain Res; 2011 Jan; 1367():310-8. PubMed ID: 20828543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Nicoletti A; Zappia M;
    Mov Disord; 2015 Nov; 30(13):1854-6. PubMed ID: 26769461
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
    Biglan KM; Holloway RG; McDermott MP; Richard IH;
    Neurology; 2007 Jul; 69(2):187-95. PubMed ID: 17620552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Kelly MJ; Lawton MA; Baig F; Ruffmann C; Barber TR; Lo C; Klein JC; Ben-Shlomo Y; Hu MT
    Mov Disord; 2019 Aug; 34(8):1174-1183. PubMed ID: 31283854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
    Antonini A; Poewe W
    Lancet Neurol; 2014 Aug; 13(8):748-9. PubMed ID: 25008550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.